This, combined with the stabilization of the gut microflora ecosystem, particularly through the inhibition of pathogens like Clostridium perfringens , leads to improved feed utilization and growth performance, especially under suboptimal hygienic conditions
For cagrilintide , Phase 2 data has shown meaningful weight loss when used as monotherapy, and the CagriSema combination (cagrilintide plus semaglutide) has entered Phase 3 trials under the REDEFINE programme by Novo Nordisk
[5] [6] It should not be used outside of regulated clinical trial settings
These risks include dosing errors, sterility concerns, counterfeit products, altered bioavailability, and reduced clinician oversight in some settings
Check whether purity data are supported by analytical testing